Literature DB >> 17133135

Relative delivery efficiency and convenience of spray and ointment formulations of papain/urea/chlorophyllin enzymatic wound therapies.

Dorothy Weir1, Kathleen L Farley.   

Abstract

OBJECTIVE: To determine the relative delivery efficiency and user preference for spray and ointment formulations containing papain, urea, and chlorophyllin copper complex sodium (papain/urea/chlorophyllin copper complex).
METHODS: Participants applied both a spray and 3 ointment formulations of papain/urea/chlorophyllin copper complex to identical wound models. The average amount of product used per application was determined by weighing the bottle or tube before the study and after completion of the study. Participants were also asked to fill out a questionnaire regarding their preferences for the two formulations.
RESULTS: The amount of product used per wound application was 30% less with the spray formulation; resulting in 29% more wound applications per container. Over 80% of the study participants found the spray easier and quicker to use than the ointments.
CONCLUSIONS: The spray formulation of papain/urea/chlorophyllin copper complex resulted in less product use per wound application than did 3 different ointment formulations. Participants expressed a favorable impression of practical benefits of the spray formulation including a reduced risk of wound contamination.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17133135     DOI: 10.1097/00152192-200609000-00005

Source DB:  PubMed          Journal:  J Wound Ostomy Continence Nurs        ISSN: 1071-5754            Impact factor:   1.741


  1 in total

1.  Papain Degrades Tight Junction Proteins of Human Keratinocytes In Vitro and Sensitizes C57BL/6 Mice via the Skin Independent of its Enzymatic Activity or TLR4 Activation.

Authors:  Caroline Stremnitzer; Krisztina Manzano-Szalai; Anna Willensdorfer; Philipp Starkl; Mario Pieper; Peter König; Michael Mildner; Erwin Tschachler; Ursula Reichart; Erika Jensen-Jarolim
Journal:  J Invest Dermatol       Date:  2015-02-23       Impact factor: 8.551

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.